ERBB2 and breast carcinoma: Consequently, in the era of anti-HER2 targeted therapy, whether patients with HER2-overexpressing breast cancer with 1-3 positive axillary lymph nodes can also be considered clinically low risk and have the opportunity for reduced postoperative radiotherapy is a clinically relevant question that warrants further investigation.